Hostname: page-component-5c6d5d7d68-ckgrl Total loading time: 0 Render date: 2024-08-16T15:35:55.706Z Has data issue: false hasContentIssue false
  • English
  • Français

Migraine and Oral Contraceptives

Published online by Cambridge University Press:  18 September 2015

W.J. Becker
W.J. Becker*
Affiliation:
University of Calgary and Calgary General Hospital, Bow Valley Centre, Calgary.
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Initiation of oral contraceptive (OC) therapy in migraine may worsen pre-existing migraine or change the pattern of the individual migraine attacks. Many women experience no change in their migraine and a few show improvement. Evidence is accumulating that migraine increases ischemic stroke risk and that this risk is higher in migraine with aura than in migraine without aura. OCs also increase stroke risk, and the increased stroke risk attributable to each of migraine and OC therapy may be additive. The risk of ischemic stroke in young women is very low and likely remains acceptably low in young women with migraine without aura and in those with a simple migraine aura when OCs are prescribed. However, the presence of a complex or prolonged migraine aura, or of additional stroke risk factors such as increased age, smoking, and hypertension likely increases the ischemic stroke risk further in patients with migraine when OCs are prescribed. Whether OCs can be prescribed safely for the patient with migraine depends upon many factors including patient age, type of migraine, and the presence or absence of other stroke risk factors.

Résumé:

RÉSUMÉ:

La prise de contraceptifs oraux peut aggraver les symptômes chez une migraineuse ou modifier le tableau clinique lors des crises. Plusieurs femmes ne présentent pas de changement de leur symptomatologie migraineuse et un petit nombre note une amélioration. II y a de plus en plus d'évidence que la migraine augmente le risque d'accident vasculaire cérébral ischémique et que ce risque est plus éevé dans la migraine avec aura que dans la migraine sans aura. Les contraceptifs oraux augmentent également le risque d'accident vasculaire cérébral et les risques accrus d'accident vasculaire cérébral attribuable à chacun pourraient être additifs. Le risque d'un accident vasculaire càrébral ischémique chez une femmejeune est très faible et demeurera probablement àun niveau acceptable chez les jeunes femmes migraineuses sans aura et chez celles qui ont une aura simple quand les contraceptifs oraux sont prescrits. Cependant, la présence de migraine avec aura complexe ou prolongée ou de facteurs de risque additionnels d'accident vasculaire cérébral tels que l'âge, le tabagisme et l'hypertension augmente vraisemblablement davantage le risque d'accident vasculaire cérébral ischémique chez les migraineuses quand on present des contraceptifs oraux. La sécurité de la prescription de contraceptifs oraux chez les patientes migraineuses dépend de plusieurs facteurs incluant l'âge de la patiente, le type de migraine et la présence ou l'absence d'autres facteurs de risque d'accident vasculaire cérébral.

Type
Review Articles
Information
Canadian Journal of Neurological Sciences , Volume 24 , Issue 1 , February 1997 , pp. 16 - 21
Copyright
Copyright © Canadian Neurological Sciences Federation 1997

References

REFERENCES

1. Bickerstaff, ER Neurological complications of oral contraceptives. Clarendon Press, Oxford, UK, 1975.Google Scholar
2. Larsson-Cohn, U, Lundberg, PO Headache and treatment with oral contraceptives. Acta Neurol Scand 1970; 46: 267–278.Google Scholar
3. Bousser, M-G, Maissiou, H. In: Olesen, J, Felt-Hansen, P , Welch, KMA, eds. The Headaches. New York: Raven Press, 1993: 413–419.Google Scholar
4. Kudrow, L The relationship of headache frequency to hormonal use in migraine. Headache 1975; 15: 36–49.CrossRefGoogle ScholarPubMed
5. Phillips, BM Oral contraceptive drugs and migraine. Br Med J 1968; 2: 99.CrossRefGoogle ScholarPubMed
6. Whitty, CWM, Hockaday, JM Migraine: a follow-up study of 92 patients. Br Med J 1968; 1: 735–736.Google Scholar
7. Bergeron, RT, Wood, EH Oral contraceptives and cerebrovascular complications. Radiology 1969; 92: 231–238.CrossRefGoogle ScholarPubMed
8. Gardner, JH, Hornstein, S, Van Den Noort, S The clinical characteristics of headache during impending cerebral infarction in women taking oral contraceptives. Headache 1968; 8: 108–111.Google Scholar
9. Silberstein, SD, Merriam, GR Sex hormones and headache. J Pain and Symptom Management 1993; 8(2): 98–114.Google Scholar
10. Goldzieher, JW, Moses, LE, Averkin, E, Scheel, C, Taber, BZ A placebo- controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil and Steril 1971; 22(9): 609–623.CrossRefGoogle ScholarPubMed
11. deBelleroche, J, Joseph, R, D’Andrea, G In: Olesen, J, Felt-Hansen, P, Welch, KMA, eds. The Headaches. New York: Raven Press, 1993: 185–191.Google Scholar
12. Gawel, MJ, Rose, FC Platelet function in migraineurs. Adv Neurol 1982;33:237–242.Google Scholar
13. Gawel, MJ Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgial 1988; 8 (Suppl 7): 1–96.Google Scholar
14. Gawel, MJ Collaborative Group for the Study of Stroke in Young Women. Oral contraceptives and stroke in young women. JAMA, Feb 1975; 231(7): 718–722.Google Scholar
15. Tzourio, C, Iglesias, S, Hubert, J-B, et al. Migraine and risk of ischemic stroke: a case-control study. Br Med J 1993; 307: 289–292.Google Scholar
16. Tzourio, C, Tehindrazanarivelo, A, Iglesias, S, et al. Case-control study of migraine and risk of ischaemic stroke in young women. Br Med J 1995;310:830–833.Google Scholar
17. Burkman, RT Lipid metabolism effects with desogestrel-containing oral contraceptives. Am J Obstet Gynecol 1993; 168: 1033–1040.Google Scholar
18. Shoupe, D Effects of desogestrel on carbohydrate metabolism. Am J Obstet Gynecol 1993; 168: 1041–1047.Google Scholar
19. Burkman, RT Desogestrel: A progestin for the 1990s. Am J Obstet Gynecol 1993; 168: 1009.Google Scholar
20. Meade, TW, Greenberg, G, Thompson, S G Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-ug oestrogen preparations. Br Med J 1980: 1157–1161.Google Scholar
21. Stadel, BV Oral contraceptives and cardiovascular disease. N Engl J Med 1981; 305(11): 612–677.Google Scholar
22. Stadel, BV Royal College of General Practitioners’ Oral Contraception Study. Further analyses of mortality in oral contraceptive users. Lancet 1981:541–550.Google Scholar
23. Porter, JB, Hunter, JR, Danielson, DA, Jick, H, Sterachis, A Oral contraceptives and nonfatal vascular disease – recent experience. Obstet Gynecol 1982; 59:299.Google Scholar
24. Mettinger, KL, Soderstrom, CE, Allander, E Epidemiology of acute cerebrovascular disease before the age of 55 in the Stockholm County 1973–77: I. Incidence and Mortality Rates. Stroke 1984; 15(5): 795–801.Google Scholar
25. Leno, C, Berciano, J, Combarros, O, et al. A prospective study of stroke in young adults in Cantabria, Spain. Stroke 1993; 24: 792–795.Google Scholar
26. Nencini, P, Inzitari, D, Baruffi, MC, et al. Incidence of stroke in young adults in Florence, Italy. Stroke 1988; 19: 977–981.Google Scholar
27. Kittner, SJ, McCarer, RJ, Sherwin, RW, et al. Black-white differences in stroke risk among young adults. Stroke 1993; 24 (Suppl 1): 113–115.Google Scholar
28. Stewart, WF, Lipton, RB, Celentano, DD, et al. Prevalence of migraine headache in the United States. JAMA 1992; 267: 64–69.Google Scholar
29. Marini, C, Carolei, A, Roberts, RS, et al. Focal cerebral ischemia in young adults: a collaborative case-control study. Neuroepidemiology 1993; 12: 70–81.Google Scholar
30. Broderick, JP, Swanson, JW Migraine-related strokes. Clinical profile and prognosis in 20 patients. Arch Neurol 1987; 44: 868–871.Google Scholar
31. Rothrock, J, North, J, Madden, K, et al. Migraine and migrainous stroke: risk factors and prognosis. Neurology 1993; 43: 2473–2476.Google Scholar
32. Wong, MCW, Giuliani, MJ, Haley, EC Cerebrovascular disease and stroke in women. Cardiology 1990: 77 (Suppl 2): 80–90.Google Scholar
33. Mattson, RH, Rebar, RW Contraceptive methods for women with neurologic disorders. Am J Obstet Gynecol 1993; 168: 2027–2032.Google Scholar
34. Silberstein, SD, Saper, JR Wolfe’s Headache and Other Head Pain (6th Ed). In: Dalessio, DJ, Silbertstein, SD, eds. New York: Oxford University Press, 1993: 96–170.Google Scholar
35. Raskin, NH Headache (2nd Ed.) New York: Churchill Livingstone. 1988: 154.Google Scholar
36. Somerville, BW The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 1972; 22: 355–365.CrossRefGoogle ScholarPubMed
37. Silberstein, SD, Merriam, GR Estrogens, progestins and headache. Neurology 1991;41:786–793.Google Scholar
38. DeLignieres, B, Vincens, M, Mauvais-Jarvis, P, et al. Prevention of menstrual migraine by percutaneous oestradiol. Br Med J (Clin Res) 1986; 293: 1540.Google Scholar
39. Dennerstein, L, Morse, C, Burrows, G, et al. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynec Endocrinol 1988,2: 113–120.Google Scholar
40. Bousser, MG, deLignieres, B, Vincens, M, Mas, JL Percutaneous estradiol treatment in menstrual migraine. In: Ferrari, MD and Lataste, X, eds. Migraine and Other Headaches. Clinical Neurology series, Park Ridge. New Jersey: The Parthenon Publishing Group, 1989.Google Scholar
41. Silberstein, SD The role of sex hormones in headache. Neurology 1992; 42 (Suppl 2): 37–42.Google Scholar